Amanote Research
Register
Sign In
SAT0480 Comparative Effectiveness of Secukinumab and Infliximab in Psoriatic Arthritis Assessed by Matching-Adjusted Indirect Comparison Using Pivotal Phase 3 Clinical Trial Data
doi 10.1136/annrheumdis-2017-eular.5802
Full Text
Open PDF
Abstract
Available in
full text
Date
June 1, 2017
Authors
V Strand
I McInnes
P Mease
E Choy
P Nash
H Thom
C Kalyvas
K Gandhi
L Pricop
S Jugl
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism
Related search
Matching-Adjusted Indirect Comparison: Secukinumab Versus Infliximab in Biologic-Naive Patients With Psoriatic Arthritis
Journal of Comparative Effectiveness Research
Health Policy
Comparative Effectiveness of Treatments for Relapsed or Refractory Mantle Cell Lymphoma (R/R McL), Using Matching Adjusted Indirect Comparison
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Real-World Data on Secukinumab Use for Psoriatic Arthritis and Ankylosing Spondylitis
Therapeutic Advances in Musculoskeletal Disease
Rheumatology
Orthopedics
Sports Medicine
Prm236 - Calibrating Matching Adjusted Indirect Comparison Estimate to Real-World Population
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Matching-Adjusted Indirect Comparison of Benralizumab Versus Interleukin-5 Inhibitors: Systematic Review
European Respiratory Journal
Medicine
Pulmonary
Respiratory Medicine
Interleukin-17inhibition With Secukinumab Improves Sudomotor Dysfunction in Psoriatic Arthritis
International Journal of Pharmacy and Pharmaceutical Sciences
Pharmacology
Pharmaceutical Science
Comparative Efficacy of Combination Immunotherapy and Targeted Therapy in the Treatment of BRAF-mutant Advanced Melanoma: A Matching-Adjusted Indirect Comparison
Immunotherapy
Oncology
Allergy
Immunology
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results From the Phase 3 FUTURE 1 Study
ACR Open Rheumatology
Pms28 - Secukinumab Versus Infliximab in the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis Among 48 Weeks From a Tunisian Perspective.
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
